The race and dose of chemotherapy should be considered for optimizing maintenance therapy for acute promyelocytic leukemia

Leukemia Research

Volumn 33, Issue 10, 2009, Pages 1427-1429

  Nagai, Sumimasa ^a   Nannya, Yasuhito ^a   Hangaishi, Akira ^a   Takahashi, Tsuyoshi ^a   Kurokawa, Mineo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Maintenance therapy; Mercaptopurine; Methotrexate

Indexed keywords

ANTHRACYCLINE; CYTARABINE; DAUNORUBICIN; IDARUBICIN; MERCAPTOPURINE; MESSENGER RNA; METHOTREXATE; MITOXANTRONE; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CYTOPENIA; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; LIVER DYSFUNCTION; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MALE; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RACE DIFFERENCE; THROMBOCYTOPENIA; TREATMENT DURATION;

6-MERCAPTOPURINE; ADULT; AGED; ANTINEOPLASTIC AGENTS; CONTINENTAL POPULATION GROUPS; DRUG TOLERANCE; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; METHOTREXATE; MIDDLE AGED; TRETINOIN;

EID: 67649352722     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.03.021     Document Type: Article

References (8)

1. Fenaux P., Chastang C., Chevret S., Sanz M., Dombret H., Archimbaud E., et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 94 (1999) 1192-1200
2. Avvisati G., Petti M.C., Lo Coco F., Testi A.M., Fazi P., Specchia G., et al. AIDA: The Italian Way of treating acute promyelocytic leukemia (APL), Final act. ASH Annual Meeting Abstracts. Blood 102 (2003) [abstract 142a]
3. Sanz M.A., Grimwade D., Tallman M.S., Lowenberg B., Fenaux P., Estey E.H., et al. Guidelines on the management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113 (2009) 1875-1891
4. Asou N., Kishimoto Y., Kiyoi H., Okada M., Kawai Y., Tsuzuki M., et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 110 (2007) 59-66
5. Schlenk R.F., Germing U., Hartmann F., Glasmacher A., Fischer J.T., del Valle y Fuentes F., et al. High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia 19 (2005) 978-983
6. Ades L., Chevret S., Raffoux E., de Botton S., Guerci A., Pigneux A., et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 24 (2006) 5703-5710
7. Sanz M.A., Montesinos P., Vellenga E., Rayon C., de la Serna J., Parody R., et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood 112 (2008) 3130-3134
8. Matasar M.J., Ritchie E.K., Consedine N., Magai C., and Neugut A.I. Incidence rates of acute promyelocytic leukemia among Hispanics, blacks, Asians, and non-Hispanic whites in the United States. Eur J Cancer Prev 15 (2006) 367-370